Dr. Navad Wallis
Post-Doctoral Fellow
Cellular and Molecular Medicine
Summary
Nadav completed his M.Sc. and Ph.D. in the lab of Prof. Joel Yisraeli at the Department of Developmental Biology and Cancer Research, The Hebrew University of Jerusalem. Prior to his doctoral studies, Nadav earned a B.Sc. in a Combined Program of Chemistry and Biology from the Open University.
During his Ph.D. research, Nadav discovered novel inhibitors of the IGf2BP1 RNA-binding protein, offering promising avenues for cancer therapeutics. His work has earned him the 2022 Kaye Innovation Award for first-year students at the Hebrew University.
In 2023, Nadav embarked on his post-doctoral journey with the Yeo lab. His current focus is to develop new technologies to identify novel small molecules capable of inhibiting RNA binding and apply these small molecules as chemical tools to deepen our understanding of the function and activity of RNA-binding proteins (RBPs).
Education
BSc/BA. Biology and Chemistry from the Open University in Israel, 2017
MSc /MA in biomedical science, dev. And cancer research department, at the Hebrew University in Jerusalem, 2018
Ph.D. in biomedical science, dev. And cancer research department, at the Hebrew University in Jerusalem, 2023
Contact
nwallis@ucsd.edu
Publications
Wallis N., Oberman F., Shurrush K., Germain N., Greenwald G., Gershon T., Pearl T., Abis G., Singh V., Singh A., Sharma A. K., Barr H. M., Ramos A., Spiegelman V. S., & Yisraeli J. K. 2022, 'Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells', RNA Biology, vol. 19, no. 1, pp. 26-43. https://doi.org/10.1080/15476286.2021.2010983